Oxcarbazepine for Mood Disorders
2002; American Psychiatric Association; Volume: 159; Issue: 10 Linguagem: Inglês
10.1176/appi.ajp.159.10.1793
ISSN1535-7228
Autores Tópico(s)Pharmacological Effects and Toxicity Studies
ResumoBack to table of contents Previous article Next article Letter to the EditorFull AccessOxcarbazepine for Mood DisordersSUHAYL NASR, M.D., SUHAYL NASR, M.D., Michigan City, Ind.Published Online:1 Oct 2002https://doi.org/10.1176/appi.ajp.159.10.1793AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the editor: The Food and Drug Administration approved oxcarbazepine on Jan. 14, 2000, for the treatment of epilepsy. It has been reported to be effective in the treatment of mood disorders (1, 2). This report is about four Caucasian patients with bipolar II disorder with comorbid substance abuse who experienced significant improvement with oxcarbazepine.Mr. A was a 52-year-old married man who was referred by a therapist in his employment assistance program for hostile behavior, which affected his relationships with family members and co-workers. He had been treated unsuccessfully with divalproate and psychotherapy. He began oxcarbazepine monotherapy, up to 1200 mg/day. He experienced better work productivity, an absence of physical violence toward his wife and co-workers, and fewer depressive days. He reported no side effects.Ms. B was a 27-year-old single woman who was in treatment for childhood sexual abuse, self-mutilation, several suicide attempts, and episodic violent behavior. Since her adolescence, she had been in numerous inpatient and outpatient treatments, which had not produced significant improvement in her symptoms or function. Oxcarbazepine was initially added to her regimen of lorazepam, buproprion, fluvoxamine, trazodone, quetiapine, levothyroxine, and modafinil. Over the next year, she reduced her medications to oxcarbazepine, 600 mg b.i.d., levothyroxine, and trazodone. She had no hospitalizations and no temper outbursts or depressive episodes, was working full-time, and was not receiving Medicaid.Mr. C was a 40-year-old married man who was referred to the clinic for treatment of agitation and conflict with his wife. He was taking buspirone, buproprion, and lithium. Oxcarbazepine, up to 1200 mg/day, was added to his dose of lithium, 900 mg/day. His irritability decreased, his depression lifted, his relationship with his wife improved, and he obtained full-time employment. In the past year, he has been well maintained with oxcarbazepine, 1200 mg b.i.d., and modafinil, 400 mg/day, before his shift work.Mr. D was a 33-year-old man who was referred for treatment of domestic violence. He began oxcarbazepine monotherapy, up to 1200 mg/day. Since then, he has controlled his angry outbursts, felt happier, improved his home life, reduced his alcohol and cannabis consumption to occasional use, and given up his part-time job as a bar bouncer. His friends have also noted the improvement.These patients were initially given 150 mg/day of oxcarbazepine; the dose was increased every 3–4 days by 150 mg until it reached 600 mg at bedtime. Morning dosing was then added, as needed, up to the maximum dose reported per patient. None of these patients had developed hyponatremia when tested within 1 month of initiation of treatment.These patients showed improvement in mood stabilization. Oxcarbazepine was well tolerated and was the initiating factor in decreasing their symptoms of anger and irritability, as well as their depressive symptoms. We have also reported separately on the benefits of oxcarbazepine in a series of 87 patients with various subtypes of mood disorders (3). Prospective, double-blind, placebo-controlled trials of oxcarbazepine are indicated.References1. Emrich HM, Altmann H, Dose M, von Zerssen D: Therapeutic effects of GABA-ergic drugs in affective disorders: a preliminary report. Pharmacol Biochem Behav 1983; 19:369-372Crossref, Medline, Google Scholar2. Emrich HM, Dose M, von Zerssen D: The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8:243-250Crossref, Medline, Google Scholar3. Nasr SJ, Casper ML: Oxcarbazepine use in the treatment of mood disorders, in 2002 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, p 117Google Scholar FiguresReferencesCited byDetailsCited byOxcarbazepine for Behavioral Disorders after Brain Injury: Factors Influencing Efficacy19 July 2021 | Brain Sciences, Vol. 11, No. 7Medikamente zur Behandlung bipolarer affektiver StörungenCochrane Database of Systematic ReviewsOxcarbazepine for the Treatment of TrichotillomaniaClinical Neuropharmacology, Vol. 33, No. 2Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: A pilot study16 April 2020 | European Psychiatry, Vol. 24, No. 3Advances in Therapy, Vol. 25, No. 7Human Psychopharmacology: Clinical and Experimental, Vol. 22, No. 3Expert Review of Neurotherapeutics, Vol. 7, No. 6Oxcarbazepine in the Treatment of Bipolar Disorder: A Review1 July 2006 | The Canadian Journal of Psychiatry, Vol. 51, No. 8Levetiracetam for Mood Stabilization and Maintenance of Seizure Control Following Multiple Treatment Failures1 November 2005 | Annals of Pharmacotherapy, Vol. 39, No. 11Pharmacotherapy of Alcohol Use Disorders3 July 2009 | Substance Use & Misuse, Vol. 40, No. 13-14Schizophrenia Bulletin, Vol. 32, No. 4CNS Spectrums, Vol. 8, No. 12Inpharma Weekly, Vol. &NA;, No. 1361 Volume 159Issue 10 October 2002Pages 1793-1793 Metrics PDF download History Published online 1 October 2002 Published in print 1 October 2002
Referência(s)